On September 6, 2024, the Colorado Prescription Drug Affordability Board (PDAB) and Prescription Drug Affordability Council (PDAC) convened to discuss the affordability review and the upper payment limit (UPL) process. The Board disagreed with stakeholder concerns urging the Board to delay the UPL-setting process, reasoning that slowing down would not resolve outstanding questions and highlighting that patients are already experiencing limited access to medications. The Board, having worked on this issue for years, believes it is time to move forward with a conservative approach.
The discussion also covered the impact of UPL, specifically the potential for reduced availability of certain drugs, and there was a focus on modeling patient costs at the point of sale. Moving forward, the Board and Council will compile a comprehensive list of questions for further examination.
Survey feedback underscored the need for more effective and diverse stakeholder involvement, improved public engagement, and standardized methods for collecting input. Stakeholder engagement for UPLs will increase this fall, with opportunities such as office hours and a stakeholder meeting on September 24.
Lastly, in terms of rulemaking, updates to the affordability rule have been made, and the Board is seeking stakeholder feedback on the redlined rules. On September 24, PDAB staff will hold a stakeholder meeting to discuss affordability review rule and policy, and on October 18th, the Board will hold the first rulemaking hearing. View the meeting slides.
Register for upcoming meetings.
Last Updated on October 14, 2024 by Aimed Alliance
